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Abstract
We report six adult patients with Tyrosinaemia type 1 (HT-1) who presented
with recurrent porphyria-like neurological crises after discontinuation/interrup-
tion of 2-(2-nitro-4-trifluoro-methylbenzyol)-1,3 cyclohexanedione (NTBC)
treatment. The crises were life-threatening for some of the patients, with respi-
ratory muscle paralysis requiring ventilatory support, hemodynamic disturbance
due to autonomic changes requiring resuscitation, acute progressive ascending
motor neuropathy causing profound impairment, recurrent seizures, and neu-
ropathic pain. Our patients’ porphyria-like presentations were variably misdiag-
nosed, with delay to diagnosis resulting in more severe recurrent attacks. We
report the first series of neurological crises in adult patients with HT-1. These
crises, which may be fatal, can be prevented and treated effectively with neurol-
ogist/physician awareness and patient education.
Introduction
Tyrosinemia type 1(HT-1) is a rare autosomal recessive
inherited metabolic disorder (OMIM #276700) caused by a
defect in fumarylacetoacetate hydrolase (EC: 3.7.1.2), a key
enzyme in the final step of tyrosine metabolism. As a result
of the metabolic block, toxic metabolites such as
succinylacetone, maleylacetoacetate, and fumarylacetoac-
etate accumulate in tissues and body fluids (Fig. 1).1 HT-1
usually manifests in the first year of life with failure to
thrive, acute and chronic liver failure, a Fanconi-like syn-
drome, renal failure, neurological crisis resembling acute
intermittent porphyria (AIP), and hepatocellular carci-
noma. If untreated, for most patients, life expectancy rarely
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extends beyond 3 years.2 Since the introduction of 2-(2-ni-
tro-4-trifluoro-methylbenzyol)-1,3 cyclohexanedione
(NTBC) as a treatment in 1992,3 the natural history of the
disease has transformed, with almost all early treated
patients now surviving to adulthood. This medical success
story relies on parents’ and patients’ perseverance in adher-
ing to treatment which includes lifelong medication and
natural dietary protein restriction, in conjunction with tyr-
osine- and phenylalanine-free protein substitutes.
The clinical consequences of NTBC discontinuation on
subsequent neurological crises are not well-documented
and there is no published evidence to guide how best to
care for these patients during such crises. To our knowl-
edge, this is the first published description of adult HT-1
patients’ pre- or post-NTBC therapy.
Case Reports
We report the United Kingdom experience of six patients
with HT-1 from three adult metabolic centers who pre-
sented with a porphyria-like neurological crisis after dis-
continuing or interrupting their NTBC treatment.
The patients’ characteristics and clinical course are
shown in Table 1. The majority were diagnosed in infancy
following an initial presentation with liver failure and
were commenced on NTBC shortly afterwards. Hepatic
and renal complications resolved on treatment and all
patients were well throughout childhood and adolescence
with no further hepatic and/or renal complications. The
mean  SD age at the time of the most severe neurologi-
cal crisis in adulthood was 23  3 years. The patients
experienced between 1 and 15 episodes each of varying
severity, with a cumulative total of at least 40 hospital
attendances. All patients had variable or intermittent
compliance with their NTBC treatment during the
months leading up to their acute neurological presenta-
tion. Although some patients were aware of the risk of a
neurological crisis if they did not take their medication,
they principally thought of their condition as a “liver dis-
ease.” Consequently, when they presented to the emer-
gency department (ED) the connection between
nonadherence to NTBC treatment and neurological
decompensation was often not made and therefore did
not form part of the initial differential diagnosis.
Case descriptions of each patient’s most
clinically severe episode
Case 1
A 26-year-old man, known to be intermittently adherent
to prescribed NTBC medication, presented with
confusion, agitation, and hallucinations whilst on a trip
abroad. He developed severe abdominal pain, anorexia,
and vomiting. He was transferred back to a UK hospital
4 days after onset of these initial symptoms. Over the
course of a few days he developed global motor weak-
ness, peripheral neuropathy, and respiratory failure
requiring intubation. The initial differential diagnosis
included Guillain-Barre Syndrome. A 6 month ITU
admission was followed by a 4 month period of intensive
inpatient rehabilitation. He had residual lower limb
weakness on discharge, which resolved by 1 year follow-
ing presentation.
Case 2
A 21-year-old man, who had only intermittently taken his
prescribed NTBC over the previous 6 months, was
brought to the ED following two generalized tonic-clonic
seizures. On admission, he was in respiratory distress, agi-
tated and combative with a severe bite mark on his ton-
gue. He required intubation and ventilation in intensive
care. Although hypertensive he was clinically hypovolemic
and hyponatremic (Na 127 mmol/L). He had mild neu-
trophilia with normal C-reactive protein (CRP). Infective
encephalitis was considered in the differential. Treatment
included antiviral, antifungal and antibiotic medications
with cautious fluid replacement.
Case 3
A 25 year old man presented to the ED with irritability,
painful extremities, severe abdominal pain, blurred vision
and a generalized tonic-clonic seizure after he discontin-
ued his NTBC treatment 1 month prior to this. On
admission he was hypertensive and tachycardic. He was
treated with supportive measures, heme arginate infusion
and NTBC and symptoms resolved.
Case 4
A 22 year old female presented to the ED with a one
week history of severe lower abdominal pain, intractable
vomiting and constipation after stopping NTBC for
2 weeks. Despite documented hypertension (147/98),
clinically she was hypovolemic, and was admitted under
the surgical team after fluid resuscitation. An abdominal
X-ray showed fecal impaction with dilated bowel but a
CT abdomen did not reveal any bowel obstruction. She
had no evidence of infection with a normal white cell
count, CRP, and serum amylase. Her symptoms
improved rapidly upon resumption of NTBC and sup-
portive therapy.
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Case 5
A 26 year old female was brought to the ED with confu-
sion following a generalized tonic-clonic seizure. A week
prior to her admission she suffered from severe abdomi-
nal pain and vomiting after stopping NTBC. During
admission, she had persistent tachycardia, hyponatremia
(Na 110 mmol/L), and developed severe proximal muscle
weakness with type 2 respiratory failure, requiring intuba-
tion and later tracheostomy for slow respiratory weaning.
Neurophysiological studies showed proximal patchy neu-
ropathy and myopathy. She recovered upon resumption
of NTBC and after extensive rehabilitation.
Case 6
A 24 year old male presented to the ED with a 3 day his-
tory of worsening abdominal pain, vomiting and poor
oral intake. During admission he had tachycardia (120–
130 beats per minute) and severe pain in his abdomen
and extremities. He required nasogastric nutrition. Man-
agement included doubling of his usual dose of NTBC,
tyrosine-free amino acid supplements, hydration (both
via enteral feed and intravenously), and propranolol to
control tachycardia.
Table 2 summarizes the clinical and biochemical char-
acteristics of the most severe episodes. As with acute
intermittent porphyria crises, abdominal pain, painful
extremities, hypertension, and hyponatremia (Na = 110–
127 lmol/L) were common findings.
In all, severe neurological crises were managed by sup-
portive therapy and NTBC (re)commencement. All
patients had an eventual full recovery within a time inter-
val ranging from 2 weeks to 12 months.
Discussion
This case series illustrates the severity, relatively common
occurrence, and challenge of acute neurological crisis
management in young adults with HT-1. It emphasizes
the need for vigilance and education of both clinicians
and young adults with HT-1 about the risk of this life-
threatening but preventable neurological crisis. As there
are no recommendations on the management of porphyr-
ia-like crises in HT-1, based on our experience and pre-
NTBC evidence, we sought to review crisis management.
In the largest cohort published to date, 104 hospital
admissions due to neurological crisis were reported in 20
of 48 children with HT-1 during the first year of life prior
to treatment with NTBC.4 Untreated childhood HT-1 is
therefore well-known to be associated with neurological
crisis and treatment with NTBC has effectively eliminated
this risk. However, when adolescent or adult patients dis-
continue or only very intermittently take NTBC, there is
also a high likelihood of developing a neurological crisis.
This is the first case series of adults with HT-1 presenting
with recurrent crises, although a single adolescent case
has previously been reported.5 Typically, the crises fol-
lowed a course of poor treatment compliance associated
with recurrent abdominal pain and vomiting. During
these severe crises patients presented with seizures, confu-
sion, painful paraesthesia, autonomic signs, hyponatremia,
self-mutilation, respiratory muscle paralysis and progres-
sive ascending paralysis. These neurological crises in
Table 2. Clinical and biochemical features during acute crises.
Findings Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6
Confusion Yes Yes Yes No Yes No
Seizures No Yes Yes No Yes No
Muscle weakness Yes Yes No No Yes No
Pain in extremities Yes Yes Yes Yes Yes Yes
Abdominal pain Yes Yes Yes Yes Yes Yes
Vomiting Yes Yes Yes Yes Yes Yes
Hypertension (SBP> 140) Yes Yes Yes Yes Yes No
Hyponatraemia (Na < 130 mmol/L) No Yes Yes Yes Yes No
ALT> 1.5 ULN ND No No No No No
INR> 1.2 ND Yes No No No No
Increased urine porphyrin/creatinine ratio (>40) Yes — Yes y — —
Increased urine ALA/creatinine (>10 lmol/mmol) Yes — — Yes — —
Increased blood spot Succinylacetone Yes Yes Yes Yes Yes Yes
NTBC level below therapeutic range Yes Yes Yes Yes Yes No
Others Acute kidney injury - probably
related to gentamicin – resolved
on stopping antibiotic
ND, not done.
ª 2020 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association 1735
C. Dawson et al. Tyrosinemia Related Neurological Crisis
adults had a similar presentation and course as those
reported in three children whose treatment with NTBC
was interrupted.6–8
Succinylacetone, the abnormal metabolite which accu-
mulates in patients with HT-1, is an extremely potent
competitive inhibitor of d-aminolevulinic acid (ALA) in
the heme biosynthesis pathway (Fig. 1).9 Due to the bio-
chemical and clinical resemblance of HT-1 associated
neurological crises and acute intermittent porphyria
(AIP), this group of symptoms in HT-1 patients is some-
times referred to as a porphyria-like syndrome. The only
precipitant that is required to cause this type of acute cri-
sis is interruption to NTBC therapy. None of the patients
described here reported another metabolic stressor (e.g.
infection or fever) triggering their crisis.
Our patients’ presentations were variously misdiag-
nosed as urinary tract or CNS infections, acute abdomen,
epilepsy, or Guillain-Barre syndrome. In addition, some
patients were labeled as having a “functional disorder”
which resulted in mistrust of care providers, more severe
subsequent recurrent attacks and disability. This indicates
a lack of awareness of the possible re-emergence of HT-1
neurological manifestations not only by the admitting
local clinical team but also, occasionally, by specialist care
providers. Patients may not always make the association
between not taking their NTBC medication and a neuro-
logical crisis, and a medical team, unfamiliar with the
condition, may simply record a list of prescribed medica-
tions without closely enquiring how often they are taken.
The approach for treating crises in our patients was:
(1) airway protection and respiratory support during
paralysis, prompt treatment of fluid and electrolyte imbal-
ance, and symptom control for seizures, pain, vomiting,
and tachycardia as per acute porphyria emergency man-
agement national guidelines (www.BIMDG.org.uk); (2)
disease modifying therapy by the provision of adequate
calorie intake and the immediate urgent reintroduction of
NTBC orally or via NG tube; and (3) return to their
usual phenylalanine and tyrosine restricted diet within 24
to 48 h. One patient also received heme arginate. Intra-
venous glucose decreases endogenous protein breakdown,
as well as inhibiting the porphyrin-synthesizing enzyme
d-aminolevulinic acid synthase and hence plays a dual
protective role. The use of heme arginate to treat acute
porphyric-like crises associated with HT-1 has only been
reported in very few cases and its potential benefit has
not been formally evaluated.5,10 Respiratory failure and
seizures can develop rapidly, and so regular clinical moni-
toring of neurological and respiratory status is important.
In conclusion, when patients with HT-1 seek medical
help with nonspecific symptoms such as pain, vomiting,
seizure, and/or weakness, a porphyria-like neurologic cri-
sis should be considered in the differential and managed
promptly.
Figure 1. Metabolic pathways and the effect of NTBC. Deficiency of fumarylacetacetate hydrolase enzyme leads to accumulation of the
metabolites upstream. An alternative pathway then leads to accumulation of succinylacetone. Succinylacetone inhibits the second step of heme
biosynthesis leading to accumulation of aminolevulinic acid and hence a clinical picture resembling that of acute intermittent porphyria. NTBC
prevents the accumulation of the toxic metabolites.
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